Protein detail
ADA2C
Alpha-2C adrenergic receptor (Alpha-2 adrenergic receptor subtype C4) (Alpha-2C adrenoreceptor) (Alpha-2C adrenoceptor) (Alpha-2CAR)
Entry name ADA2C | UniProt ID | EVMP confidence score 0.53 |
Supporting publications (n) 2 | Transmembrane count 7 | Protein classification FDA approved drug targetsG-protein coupled receptorsPredicted membrane proteins |
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.70High >= 0.60Medium >= 0.40Low >= 0.30Basic Information
Protein Names
Alpha-2C adrenergic receptor (Alpha-2 adrenergic receptor subtype C4) (Alpha-2C adrenoreceptor) (Alpha-2C adrenoceptor) (Alpha-2CAR)
Protein Class (3)
FDA approved drug targetsG-protein coupled receptorsPredicted membrane proteins
Protein Function (2)
- FDA approved drug targets:Small molecule drugs
- G-protein coupled receptors:GPCRs excl olfactory receptors
Transmembrane
49..74; Helical; Name=1; 88..110; Helical; Name=2; 122..147; Helical; Name=3; 168..187; Helical; Name=4; 209..231; Helical; Name=5; 384..408; Helical; Name=6; 417..440; Helical; Name=7
Transmembrane Count
7
Ensembl
Entrez Gene Symbol
Gene Synonym (3)
ADRA2L2ADRA2RL2ADRARL2
Gene Description
Adrenoceptor alpha 2C
Chromosome
4
Position
3766348-3768526
Supporting publications (n)
2
EVMP confidence score
0.53
Fluorescence & Localization
Tissue Specificbone marrowCell SpecificMonocyte progenitors
Function & Pathway
Protein Function (2)
- FDA approved drug targets:Small molecule drugs
- G-protein coupled receptors:GPCRs excl olfactory receptors
Cellular Component (3)
Molecular Function (7)
Biological Process (3)
KEGG (4)
Reactome (14)
- R-hsa-400042 adrenaline noradrenaline inhibits insulin secretion
- R-hsa-390696 adrenoceptors
- R-hsa-375280 amine ligand binding receptors
- R-hsa-373076 class a 1 rhodopsin like receptors
- R-hsa-500792 gpcr ligand binding
- R-hsa-418594 g alpha i signalling events
- R-hsa-418597 g alpha z signalling events
- R-hsa-109582 hemostasis
- R-hsa-163685 integration of energy metabolism
- R-hsa-76002 platelet activation signaling and aggregation
Page 1 of 2
Canonical Pathways (3)
- M33 Pid glypican 1pathway
- M252 Pid il8 cxcr1 pathway
- M76 Pid p38 alpha beta pathway
Mediation Categories (5)
Clinical-translation mediationFusion and delivery mediationImmune mediationMetabolism mediationReceptor-signaling mediation
Relations & Evidence52
Ligand-Receptor Signaling (46)
46 records.
| Category | Parent | Database | Transmitter | Receiver | Secreted | Plasma Membrane (Transmembrane) | Plasma Membrane (Peripheral) |
|---|---|---|---|---|---|---|---|
| intracellular | intracellular | ComPPI | Yes | ||||
| intracellular | intracellular | GO_Intercell | Yes | ||||
| intracellular | intracellular | OmniPath | Yes | ||||
| transmembrane | transmembrane | UniProt_location | Yes | ||||
| transmembrane | transmembrane | UniProt_topology | Yes | ||||
| transmembrane | transmembrane | UniProt_keyword | Yes | ||||
| transmembrane | transmembrane | GO_Intercell | Yes | ||||
| transmembrane | transmembrane | CellPhoneDB | Yes | ||||
| transmembrane | transmembrane | TopDB | Yes | ||||
| transmembrane | transmembrane | LOCATE | Yes |
Regulatory Interaction Network (4)
4 records.
| Source Protein Symbol | Source UniProt ID | Target Protein Symbol | Target UniProt ID | Is Directed | Is Stimulation | Is Inhibition | Database | References |
|---|---|---|---|---|---|---|---|---|
| ADA2C | P18825 | GNAZ | P19086 | Yes | Yes | SIGNOR | SIGNOR:31160049 | |
| ADA2C | P18825 | GNAI3 | P08754 | Yes | Yes | SIGNOR | SIGNOR:31160049 | |
| ADA2C | P18825 | GNAI1 | P63096 | Yes | Yes | SIGNOR | SIGNOR:31160049 | |
| ADA2C | P18825 | GNAO | P09471 | Yes | Yes | HPRDSIGNOR | HPRD:1349607SIGNOR:31160049 |
Protein Complex Composition (1)
Isolation & Detection Technology (1)
1 record.
| EV Isolation Method | Detection Method | Number of References | References |
|---|---|---|---|
| Mass spectrometry | 0 |
Sequence, Structure & Domains
Sequences
Length
462
Mass
49,522
Sequence
MASPALAAALAVAAAAGPNASGAGERGSGGVANASGASWGPPRGQYSAGAVAGLAAVVGFLIVFTVVGNVLVVIAVLTSRALRAPQNLFLVSLASADILVATLVMPFSLANELMAYWYFGQVWCGVYLALDVLFCTSSIVHLCAISLDRYWSVTQAVEYNLKRTPRRVKATIVAVWLISAVISFPPLVSLYRQPDGAAYPQCGLNDETWYILSSCIGSFFAPCLIMGLVYARIYRVAKLRTRTLSEKRAPVGPDGASPTTENGLGAAAGAGENGHCAPPPADVEPDESSAAAERRRRRGALRRGGRRRAGAEGGAGGADGQGAGPGAAESGALTASRSPGPGGRLSRASSRSVEFFLSRRRRARSSVCRRKVAQAREKRFTFVLAVVMGVFVLCWFPFFFSYSLYGICREACQVPGPLFKFFFWIGYCNSSLNPVIYTVFNQDFRRSFKHILFRRRRRGFRQ
3D Structural Models
Helix
48..78; 80..82; 85..87; 88..103; 105..114; 120..154; 156..160; 165..183; 208..218; 220..239; 372..408; 409..412; 416..428; 429..431; 433..440; 442..452
3D Structure
X-ray crystallography (1)
Domain & Motif Annotations
Compositional Bias
294..308; Basic residues; 311..325; Gly residues
Region
246..347; Disordered
Protein Families (3)
- G-protein coupled receptor 1 family
- Adrenergic receptor subfamily
- ADRA2C sub-subfamily
Sequence Similarities
Belongs to the G-protein coupled receptor 1 family. Adrenergic receptor subfamily. ADRA2C sub-subfamily.
Clinical Relevance
Disease Involvement
FDA approved drug targets
Related Diseases (29)
Acute diabetic complicationAlzheimer diseaseAsthmaChronic arterial occlusive diseaseChronic kidney diseaseChronic painCoronavirus infectionDementiaDepressionDissociative neurological symptom disorderGeneral pain disorderGenetic cardiac arrhythmiaGlaucomaHeart failureHerpes simplex infectionHypertensionHypotensionNon-specific cutaneous vascular symptomObesityOrgasmic dysfunctionPainPeptic ulcerPost-traumatic stress disorderProstate diseaseSexual dysfunctionSubstance abuseUnspecific body region injuryUnspecific substance harmful effectVasomotor/allergic rhinitis
Biomarker
Discontinued in Phase 2; Phase 2; Terminated; Phase 3; Preclinical; Investigative; Discontinued in Phase 3; Approved; Discontinued in Preregistration; Phase 4
Drug Targets
FDA approved drug targets
Drugs (72)
TETRAHYDROZOLINE HYDROCHLORIDENAPHAZOLINE HYDROCHLORIDEVASOACTIVE INTESTINAL PEPTIDEAMOSULALOLAJMALICINELOFEXIDINENULLPROPYLHEXEDRINETETRAHYDROZOLINEEPINEPHRINE BITARTRATELOFEXIDINE HYDROCHLORIDEFIPAMEZOLEMEDETOMIDINEMIRTAZAPINENOREPINEPHRINESENREBOTASEOLANZAPINERILMENIDINEESMIRTAZAPINE MALEATECLONIDINE HYDROCHLORIDEAPRACLONIDINE HYDROCHLORIDEIDAZOXANDOPAMINEMOXISYLYTEXYLOMETAZOLINEDEBRISOQUINYOHIMBINEFENOLDOPAM MESYLATEDIHYDROERGOCRISTINETIZANIDINE HYDROCHLORIDEBETA-ALANINERAUWOLFIA SERPENTINA (USP)FADOLMIDINELEVONORDEFRINERGOLOID MESYLATES, USPMETHAMPHETAMINEEPHEDRINEERGOTAMINE TARTRATEGUANFACINE HYDROCHLORIDEEPHEDRINE HYDROCHLORIDEBUCINDOLOL HYDROCHLORIDEBETHANIDINEMETHYLDOPA ANHYDROUSISOPROTERENOLBRIMONIDINEORM-12741AMEZINIUMPHENTOLAMINE MESYLATEASENAPINEEPINEPHRINELABETALOL HYDROCHLORIDEFADOLMIDINE HYDROCHLORIDECELIPROLOLDEXMEDETOMIDINE HYDROCHLORIDEPHENOXYBENZAMINE HYDROCHLORIDEMOXONIDINEGUANABENZ ACETATENOREPINEPHRINE BITARTRATEILOPERIDONEDROXIDOPAOPC-28326MEPHENTERMINE SULFATETETRASULMETHYLDOPATE HYDROCHLORIDEOXYMETAZOLINE HYDROCHLORIDEDIPIVEFRIN HYDROCHLORIDEMETOPROLOLIDAZOXAN HYDROCHLORIDETOLAZOLINE HYDROCHLORIDEHYDROXYAMPHETAMINE HYDROBROMIDELURASIDONE HYDROCHLORIDECYCLOBENZAPRINE
Antibody
Supporting Publications2
| PMID | Title | Related sentences |
|---|---|---|
| 38731868 | The Deep Proteomics Approach Identified Extracellular Vesicular Proteins Correlated to Extracellular Matrix in Type One and Two Endometrial Cancer. | No related sentences available |
| 41227296 | Extracellular Vesicles Profiling in Acute Myeloid Leukemia Cell Lines: A Proteomic Characterization. | No related sentences available |